Cart
sales@molnova.com
Eciruciclib
CAS No. 1868086-40-1
Eciruciclib ( —— )
Catalog No. M28496 CAS No. 1868086-40-1
Eciruciclib is an inhibitor of CDK with antitumor properties.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 312 | Get Quote |
|
| 10MG | 500 | Get Quote |
|
| 25MG | 807 | Get Quote |
|
| 50MG | 1107 | Get Quote |
|
| 100MG | 1485 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEciruciclib
-
NoteResearch use only, not for human use.
-
Brief DescriptionEciruciclib is an inhibitor of CDK with antitumor properties.
-
DescriptionEciruciclib is an inhibitor of CDK with antitumor properties.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1868086-40-1
-
Formula Weight488.6
-
Molecular FormulaC27H33FN8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C1=C2C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=CC2=NN1C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Cdc7 inhibitor 7c
A highly potent, selective and time-dependent Cdc7 kinase inhibitor with IC50 of 0.7 nM with slow dissociation property, with 200-fold and >14,000-fold selectivity over CDK2 and ROCK1, respectively.
-
NSC23005 sodium
A novel specific, effective p18 (p18INK4C) inhibitor that can selectively promote HSCs expansion with EC50 of 5.21 nM.
-
CYC065
CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.
